The emergence of drug-resistant tumors during therapy for ovarian cancer remains an
obstacle to improving long-term outcomes. Active areas of ovarian cancer research include …

Although the majority of the patients with advanced ovarian cancer will die of the disease,
optimism is justified in view of the improved results of surgery followed by cisplatin-and …

Important advances in the management of advanced epithelial ovarian cancer have been
made in recent years, with much of the knowledge emanating from clinical trials conducted …

Introduction: Epithelial ovarian cancer is the most lethal gynecologic malignancy. Recent
advances in understanding the biology and its molecular and histological diversity have led …

Ovarian cancer affects 23,400 women in the United States annually and is responsible for
13,900 deaths.[1] It is the fifth most common cause of cancer deaths among women in the …

Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over
recent decades, improvements have been made in treatment outcome in terms of response …

The ovary is one of the three most common sites for the development of a malignant
neoplasm in the female genital tract. Unlike cancers of the endometrium and cervix, ovarian …

Standard chemotherapy for previously untreated patients with advanced ovarian cancer
consists of the combination of a taxane and a platinum compound. While the majority of …

Background The 5-year survival of ovarian cancer has slowly increased but to date much of
this has been due to the use of more lines of treatment rather than better first-line therapy. In …

Ovarian cancer continues to be the leading cause of death secondary to gynecologic
cancers among women in the western world. Current treatment of ovarian cancer entails a …